Automated Triage of Thyroid Cancer

73-year-old man with papillary carcinoma of left lobe of thyroid. Screen shot shows example of thyroid nodule annotation (segmentation and TI-RADS annotation) performed on ultrasound image in longitudinal projection with electronic Physician Annotation Device software (Stanford Medicine Radiology). Radiologists performed nodule segmentation by selecting points (red) on nodule outline (green), while controlling smoothing of outline polygon by means of spline interpolation.


January 30, 2020 — According to an article published ahead-of-print in the April issue of the American Journal of Roentgenology (AJR), a Stanford University team has developed a quantitative framework able to sonographically differentiate between benign and malignant thyroid nodules at a level comparable to that of expert radiologists, which may prove useful for establishing a fully automated system of thyroid nodule triage.

Alfiia Galimzianova et al. retrospectively collected ultrasound images of 92 biopsy-confirmed nodules, which were annotated by two expert radiologists using the American College of Radiology’s Thyroid Imaging Reporting and Data System (TI-RADS).

In the researchers’ framework, nodule features of echogenicity, texture, edge sharpness, and margin curvature properties were analyzed in a regularized logistic regression model to predict nodule malignancy. Authenticating their method with leave-one-out cross-validation, the Stanford team used ROC AUC, sensitivity, and specificity to compare the framework’s results with those obtained by six expert annotation-based classifiers.

The AUC of the proposed framework measured 0.828 (95% CI, 0.715–0.942) — "greater than or comparable,” Galimzianova noted, “to that of the expert classifiers”—whose AUC values ranged from 0.299 to 0.829 (p = 0.99).

Additionally, in a curative strategy at sensitivity of 1, use of the framework could have avoided biopsy in 20 of 46 benign nodules — statistically significantly higher than three expert classifiers. In a conservative strategy at specificity of 1, the framework could have helped to identify 10 of 46 malignancies — statistically significantly higher than five expert classifiers.  

“Our results confirm the ultimate feasibility of computer-aided diagnostic systems for thyroid cancer risk estimation,” concluded Galimzianova. “Such systems could provide second-opinion malignancy risk estimation to clinicians and ultimately help decrease the number of unnecessary biopsies and surgical procedures.”

For more information: www.arrs.org


Related Content

Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Feature | Radiation Dose Management | By Christine Book

Advances in the growing radiation dose management market are continually helping those who administer treatment to focus ...

Time May 03, 2024
arrow
News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
Feature | Radiology Business

Beginning this spring, ITN will begin sending out a bi-monthly survey to our readers on a variety of topics, which we ...

Time May 02, 2024
arrow
News | Breast Imaging

May 1, 2024 — After the issuance of updated breast screening recommendations by the U.S. Preventive Services Task Force ...

Time May 01, 2024
arrow
News | Ultrasound Imaging

April 30, 2024 — Best Nomos, a TeamBest Global Company, is launching its most modern, highly innovative Compact SONALIS ...

Time April 30, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
Subscribe Now